Stockreport

Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF silence both PCSK9 and APOC3 to address atherosclerotic cardiovascular disease caused by mixed hyperlipidemia. This marks the first time a single RNA interference mole [Read more]